TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04469101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Description: Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Description: Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Description: Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Epidural
Description: Parturients will have an epidural placed in the upright seated position as per institution standard. After epidural placement, they will be positioned as per their randomization. They will then have a total of 20 cc of epidural solution (0.08% ropivacaine with 2 mcg per cc of fentanyl) injected into the epidural in boluses of 5 cc every 5 minutes.
Study: NCT05921851

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04973527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of LCAR-T2C CAR-T cells
Description: CD4-directed CAR-T cells administered with lymphoid depletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
Study: NCT05157412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg Oral Tablet
Description: Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Study: NCT05450159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROADskills program
Description: Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging
Description: Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
Study: NCT06387576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally informed pre-discharge iPad video scheduling
Description: The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
Study: NCT05157412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Study: NCT05081037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Care Group
Description: Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels.
Study: NCT05115760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Given Kate Farms pea protein oral nutrition supplement PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05128656

Intervention type: OTHER
Group type: OTHER
Intervention: serology
Description: serology at M3 and serology at M6

Intervention type: OTHER
Group type: OTHER
Intervention: serology
Description: serology at M3 and serology at M6
Study: NCT05868707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OH2
Description: Oncolytic Type 2 Herpes Simplex Virus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage chemotherapy or best supportive care
Description: single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum
Study: NCT05033795

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water A
Description: 2 L of water A per day

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Water B
Description: 2 L of water B per day
Study: NCT04706065

Intervention type: GENETIC
Intervention: SHMT1 polymorphism
Description: It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.

Intervention type: GENETIC
Intervention: SHMT1 polymorphism
Description: It is to identify the role of SHMT1polymorphism in PD and examine the relationship between it and Severity of PD.
Study: NCT05696665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Patients will be kept on conventional therapy and no added drugs will be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saffron and Chamomile
Description: Patients will be given saffron and chamomile in capsule formulation twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin and Apigenin
Description: Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
Study: NCT05117658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet
Description: HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days)
Study: NCT06510257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconyl
Description: 1 tablet of Reconyl, 3 times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet of Reconyl
Description: 1 tablet of placebo Reconyl, 3 times daily
Study: NCT05208710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 10µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 10µg antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 40µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 40µg antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with PANHPVAX 100µg
Description: Escalated dosages of c-di AMP (0, 7,5, 15µg) added groupwise to 100µg antigen
Study: NCT05284162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: The health coaching program includes four monthly health coaching sessions for three months.
Study: NCT05143489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative Free Lidocaine
Description: The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: The patient will receive IV normal saline of 1mg/kg with a max of 40mg
Study: NCT05079711

Intervention type: DEVICE
Intervention: SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
Description: The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.

Intervention type: DEVICE
Intervention: SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
Description: The SavvyCheck Vaginal Yeast Test is a lateral flow immunochromatographic qualitative test for detection of Candida antigen in vaginal secretions, sampled by a swab as an aid for identification of vulvovaginal candidiasis (VVC), as a primary cause of vaginal yeast infections. The SavvyCheck Vaginal Yeast Test is designed for use by women experiencing vaginal symptoms, including: increased vaginal discharge, vaginal itching, vaginal soreness and irritation, rash on the labia, and genital burning that may worsen during urination. The SavvyCheck Vaginal Yeast Test is indicated for OTC use.
Study: NCT02014428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05049395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula oxygen (HFNO)
Description: The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular oxygen
Description: The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
Study: NCT05575193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes.
Study: NCT05767840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological interventions
Description: mhGap-IG Depression and self-harm module. For participants identified as has having depression, following interventions will be offered depending on nature of the participants.~1. Khushi Aur Khatoon - for the treatment of depression and anxiety~2. Learning through Play Plus - 10-session group intervention that integrates parental information about child development and Cognitive Behavior Therapy~3. Problem management Plus (PM+) - PM+ is for adults suffering from symptoms of common mental health problems , as well as self-identified practical problems.~Cohort identified as having a recent history of self-harm will receive; Culturally Adapted Manual Assisted Problem Solving Intervention (CMAP) - This intervention is a manual-assisted intervention, adapted from a self-help guide called Life After Self-Harm.
Study: NCT04730791

Intervention type: DIAGNOSTIC_TEST
Intervention: Algo(s)rithm/ IASP clinical criteria
Description: IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.

Intervention type: DIAGNOSTIC_TEST
Intervention: Algo(s)rithm/ IASP clinical criteria
Description: IASP clinical criteria for identifying nociplastic pain. The criteria is completed by the healthcare professional and includes questions about the patient's clinical picture.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Pain Threshold
Description: The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure Pain Threshold
Description: The pain pressure threshold (PPT) is used to measure pain sensitivity in body areas. The test quantifies the minimum amount of pressure in a given area, during an increasing skin pressure stimulus, which is capable of altering the feeling of pressure in pain.
Study: NCT05195541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Study: NCT05037565

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum
Description: Partially hydrolyzed guar gum (PHGG) is a vegetal, water soluble, non-viscous, non-gelling dietary fiber that is derived from guar gum, a water-soluble, viscous, gelling polysaccharide found in the seeds of Cyamopsis tetragonolobus. PHGG is available over the counter as a dietary supplement as fiber.
Study: NCT05028504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: A multi-target receptor tyrosine kinase inhibitor
Study: NCT06137443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Patients underwent treatment for eight weeks, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week.
Study: NCT06523322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Cook Together
Description: The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).
Study: NCT06363552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191
Description: The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191 + Bevacizumab
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191 + 5-FU/LV
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Calcium folinate 400mg/m2 intravenous infusion (over 2 hours or more), on the first day, followed by 5-fluorouracil 400mg/m2 intravenous bolus injection, then continuous intravenous infusion of 1200mg/m2/day for 2 days.
Study: NCT05016570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Picture narrative information format
Description: Lung screening information formatted as picture narratives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text with pictures information format
Description: Lung screening information formatted as text and non-narrative pictures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-only information format
Description: Lung screening information formatted as text with no pictures
Study: NCT06311981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: targeted therapy
Description: targeted therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single regimen chemotherapy in sequence with radiotherapy
Description: single regimen chemotherapy in sequence with radiotherapy
Study: NCT04988620

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood transfusion
Description: In this study the effect of storage time of whole blood will be investigated. Intervention is storage of whole blood.
Study: NCT05195541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-20401
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Study: NCT05081206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion via manually controlled pump.
Description: Patients will receive propofol bolus 2.5-3 mg/kg, for anesthesia induction and anesthesia maintenance was continued according to the Mc Farlan scheme, meaning continuous propofol infusion is used, with gradual reduction of the infusion speed in timely manner, depending on the duration of surgery: 15mg/kg/h...13mg/kg/h...11mg/kg/h...9mg/kg/h...6mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion via target controlled pump.
Description: Pedfusor model was used for delivering target controlled plasma concentration, with target concentration for anesthesia induction of 4 mcg/kg body weight and then 3 mcg/kg.
Study: NCT05778682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suctioning based protocol
Description: cf. arm The necessity of suctioning will be assed continuously by the nurses, respiratory therapist and the medical team. If the patient require 2 or less aspiration each 8 hours for 24 hours straight, an attempt of decanalution will be done.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care
Description: Usual care in our center is tolerance to a capping trial.
Study: NCT05354349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRA023 IV Low Dose
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023 SC
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo SC
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023 IV High Dose
Description: Drug
Study: NCT05287165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM96 CAR-T cells
Description: treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
Study: NCT05554666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG315
Description: Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
Study: NCT05628337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational texting
Description: Health related information relevant to a subject's diagnosis and ongoing treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non-motivational text messages containing no specific health information